Open access
Open access
Powered by Google Translator Translator

Allergy & Immunology

Booster longevity: Data reveals how long a third shot protects.

20 Jan, 2022 | 09:33h | UTC

Booster longevity: Data reveals how long a third shot protects – NPR

Original Report: SARS-CoV-2 variants of concern and variants under investigation in England – U.K. Health Security Agency

 


Milder disease with Omicron: is it the virus or the pre-existing immunity?

20 Jan, 2022 | 09:28h | UTC

Milder disease with Omicron: is it the virus or the pre-existing immunity? – Nature Reviews Immunology

 


How does Omicron spread so fast? A high viral load isn’t the answer – “Data on viral levels point to immune evasion as a cause of the variant’s transmissibility”.

20 Jan, 2022 | 09:27h | UTC

How does Omicron spread so fast? A high viral load isn’t the answer – Nature

 


A large observational study showed people with immune disfunction (HIV, solid organ transplant, rheumatoid arthritis) were at increased risk of breakthrough Covid-19 infection after vaccination.

20 Jan, 2022 | 09:24h | UTC

Association Between Immune Dysfunction and COVID-19 Breakthrough Infection After SARS-CoV-2 Vaccination in the US – JAMA Internal Medicine

 


Study provides evidence of causality between Epstein-Barr virus and multiple sclerosis.

14 Jan, 2022 | 08:23h | UTC

Longitudinal analysis reveals high prevalence of Epstein-Barr virus associated with multiple sclerosis – Science (link to abstract – $ for full-text)

Commentaries:

Strong new evidence suggests a virus triggers multiple sclerosis – STAT

Study identifies Epstein-Barr as a leading candidate for cause of Multiple Sclerosis – Uniformed Services University of the Health Sciences (USU)

Epstein-Barr virus may be leading cause of multiple sclerosis – Harvard T.H. Chan School of Public Health

 


An observational study in South Africa estimates the Pfizer vaccine had an effectiveness of 70% against hospitalization for Covid-19 caused by the omicron variant.

13 Jan, 2022 | 08:56h | UTC

Effectiveness of BNT162b2 Vaccine against Omicron Variant in South Africa – New England Journal of Medicine

Commentary: BNT162b2 still effective, but less so, against Omicron – HealthDay

 


‘Killer’ immune cells still recognize Omicron variant.

13 Jan, 2022 | 08:51h | UTC

‘Killer’ immune cells still recognize Omicron variant – Nature

See also: T-cells: the superheroes in the battle against omicron – The Conversation

 


Another study showed neutralizing monoclonal antibody therapies are not effective when given after the patient is already hospitalized.

13 Jan, 2022 | 08:48h | UTC

Efficacy and safety of two neutralising monoclonal antibody therapies, sotrovimab and BRII-196 plus BRII-198, for adults hospitalised with COVID-19 (TICO): a randomised controlled trial – The Lancet Infectious Diseases

Invited Commentary: Time to knock monoclonal antibodies off the platform for patients hospitalised with COVID-19

 


[Preprint] Lab study shows Omicron infection enhances neutralizing immunity against the Delta variant.

11 Jan, 2022 | 01:29h | UTC

Omicron infection enhances neutralizing immunity against the Delta variant – medRxiv

 


Omicron’s feeble attack on the lungs could make it less dangerous.

11 Jan, 2022 | 01:23h | UTC

Omicron’s feeble attack on the lungs could make it less dangerous – Nature

 


WHO issues interim recommendations for heterologous COVID-19 vaccine schedules.

17 Dec, 2021 | 10:01h | UTC

Interim recommendations for heterologous COVID-19 vaccine schedules – World Health Organization

Commentary: Coronavirus: WHO gives the nod for mix-and-match vaccine schedules – South China Morning Post

 


Breakthrough infections generate ‘super immunity’ to COVID-19, study suggests.

17 Dec, 2021 | 09:47h | UTC

News Release: Breakthrough infections generate ‘super immunity’ to COVID-19, study suggests – Oregon Health & Science University

Original Study: Antibody Response and Variant Cross-Neutralization After SARS-CoV-2 Breakthrough Infection – JAMA

 


T Cells might be our bodies’ best shot against Omicron.

16 Dec, 2021 | 09:45h | UTC

T Cells Might Be Our Bodies’ Best Shot Against Omicron – The Atlantic

 


SARS-CoV-2 breakthrough infections in vaccinated individuals: measurement, causes and impact.

10 Dec, 2021 | 10:23h | UTC

SARS-CoV-2 breakthrough infections in vaccinated individuals: measurement, causes and impact – Nature Reviews Immunology

 

Commentary on Twitter

 


[Press release – not published yet] Lab study suggests a third dose (booster) of the Pfizer–BioNTech vaccine may be necessary to provide an adequate immune response to the Omicron variant.

9 Dec, 2021 | 10:29h | UTC

Press release: Pfizer and Biontech provide update on Omicron variant

Commentaries:

Omicron likely to weaken COVID vaccine protection – Nature

Pfizer-BioNTech says COVID booster should protect against Omicron – CIDRAP

Expert reaction to press release from Pfizer-BioNTech about omicron and neutralising antibody titres after two and three vaccine doses – Science Media Centre

Covid: Pfizer says booster shot promising against Omicron – BBC

Pfizer-BioNTech Covid-19 shot loses power against Omicron variant, but booster restores protection – STAT

 


Multiple early studies find notable Omicron vaccine evasion.

9 Dec, 2021 | 10:26h | UTC

Multiple early studies find notable Omicron vaccine evasion – CIDRAP

Related: A first, small study suggests Omicron is a larger threat to Covid-19 immunity than other variants.

 


RCT: Among children between the ages of 6 and 11 years with uncontrolled moderate-to-severe asthma, add-on Dupilumab reduced exacerbations and improved lung function.

9 Dec, 2021 | 10:21h | UTC

Dupilumab in Children with Uncontrolled Moderate-to-Severe Asthma – New England Journal of Medicine

Commentary: International study supports dupilumab for treatment of moderate-to-severe asthma in children – Vanderbilt University Medical Center

 


A first, small study suggests Omicron is a larger threat to Covid-19 immunity than other variants.

8 Dec, 2021 | 10:22h | UTC

A first, small study suggests Omicron is a larger threat to Covid-19 immunity than other variants – STAT

Original Study: SARS-CoV-2 Omicron has extensive but incomplete escape of Pfizer BNT162b2 elicited neutralization and requires ACE2 for infection – medRxiv

 

Commentary from the author on Twitter (thread – click for more)

See also (thread – click for more)

 


Beyond Omicron: what’s next for COVID’s viral evolution.

8 Dec, 2021 | 10:06h | UTC

Beyond Omicron: what’s next for COVID’s viral evolution – Nature

 


Study shows increased immunogenicity of extended mRNA SARS-CoV-2 vaccine dosing intervals.

7 Dec, 2021 | 10:21h | UTC

Immunogenicity of Extended mRNA SARS-CoV-2 Vaccine Dosing Intervals – JAMA

 

Commentary on Twitter (thread – click for more)

 


Six different COVID-19 boosters are safe and increase immunity when given after two doses of AstraZeneca or Pfizer-BioNTech, with significant variations in immune responses, UK trial shows.

5 Dec, 2021 | 23:57h | UTC

News Release: Six different COVID-19 boosters are safe and increase immunity when given after two doses of AstraZeneca or Pfizer-BioNTech, with large variations in immune responses, UK trial shows – The Lancet

Original Study: Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial – The Lancet

Commentaries:

Six different COVID-19 boosters induce variable immune response – CIDRAP

Covid booster shots significantly strengthen immunity, trial finds – The Guardian

Expert reaction to COV-BOOST study investigating safety and immunogenicity of seven COVID-19 vaccines as a third dose following two doses of either Oxford-AstraZeneca or Pfizer – Science Media Centre

 

Commentary on Twitter

 


Omicron is supercharging the COVID vaccine booster debate – “The data are growing that booster jabs enhance protection — but their durability, impact and ability to quash the new variant are unknown”.

3 Dec, 2021 | 10:19h | UTC

Omicron is supercharging the COVID vaccine booster debate – Nature

 


Systematic Review: Phototherapy for atopic eczema.

3 Dec, 2021 | 10:03h | UTC

Phototherapy for atopic eczema – Cochrane Library

Summary: What are the benefits and risks of visible light therapy for treating atopic eczema (also known as eczema or atopic dermatitis)? – Cochrane Library

 

Commentary on Twitter

 


Cohort study: Allergic conditions linked to lower COVID-19 infection risk.

1 Dec, 2021 | 08:52h | UTC

News Release: Allergic conditions linked to lower COVID-19 infection risk – BMJ

Original Study: Risk factors for developing COVID-19: a population-based longitudinal study (COVIDENCE UK) – Thorax

 


Heavily mutated coronavirus variant puts scientists on alert – “Researchers are racing to determine whether a fast-spreading variant in South Africa poses a threat to COVID vaccines’ effectiveness”.

26 Nov, 2021 | 08:42h | UTC

Heavily mutated coronavirus variant puts scientists on alert – Nature

See also:

Covid: New heavily mutated variant B.1.1.529 in South Africa raises concern – BBC

WHO calls special meeting to discuss new Covid variant found in South Africa with ‘a large number of mutations’ – CNBC

New COVID-19 Variant With Multiple Concerning Mutations Identified in Southern Africa – Health Policy Watch

Scientists warn of new Covid variant with high number of mutations – The Guardian

South Africa detects new COVID variant with many mutations – MedicalXpress

 

Related commentary on Twitter (thread – click for more)

 


Stay Updated in Your Specialty

No spam, just news.